VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2019 | IDEA-FRANCE: ctDNA as a predictive value for adjuvant treatment duration

Thierry André • 29 Sep 2019
ESMO 2019
Colorectal Cancer Gastrointestinal Cancer
IDEA-FRANCE

Thierry André, MD, Saint-Antoine Hospital, Paris, France, talks about the IDEA-FRANCE Phase III study (NCT00958737) of ctDNA as a prognostic and predictive value for adjuvant treatment duration. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Thierry André

2:20
AVANT: bevacizumab + oxaliplatin-based chemo for colon cancer
Thierry André • 29 Sep 2019

Related Videos

6:58
Personalizing ctDNA analysis to predict CRC relapse
Gayathri Anandappa • 22 Jan 2021
4:00
Personalizing the approach to CRC
Gayathri Anandappa • 22 Jan 2021
8:45
ctDNA as a novel biomarker for MRD in CRC
Arvind Dasari • 22 Jan 2021
3:18
Real-world outcomes of patients with intrahepatic CCA treated with trans-arterial radioembolization
Thomas Helmberger • 22 Jan 2021
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals